Research Departments & Organizations
Barrett Esophagus; Bile Duct Neoplasms; Biliary Tract Diseases; Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Cholangitis; Cholangitis, Sclerosing; Cholecystitis; Cholecystitis, Acute; Cholecystolithiasis; Choledochal Cyst; Choledocholithiasis; Cholelithiasis; Cholestasis; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; Colonic Neoplasms; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Common Bile Duct Diseases; Common Bile Duct Neoplasms; Digestive System Abnormalities; Digestive System Diseases; Digestive System Neoplasms; Duodenal Neoplasms; Emphysematous Cholecystitis; Esophageal Cyst; Esophageal Diseases; Esophageal Fistula; Esophageal Neoplasms; Exocrine Pancreatic Insufficiency; Gallbladder Diseases; Gallstones; Gastric Fistula; Gastrinoma; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucagonoma; Ileal Neoplasms; Intestinal Neoplasms; Pancreatic Cyst; Pancreatic Diseases; Pancreatic Fistula; Pancreatic Neoplasms; Pancreatic Pseudocyst; Rectal Neoplasms; Stomach Neoplasms
Extensive Research Description
Dr Farrell has leveraged his clinical expertise and activities as a practicing clinical gastroenterologist, board certified clinical pharmacologist, and interventional endoscopist to create a successful clinical and translational research program focused on pancreatic cancer in the areas of early pancreatic cancer diagnosis, pancreatic cystic neoplasms and pancreatic cancer therapeutics and pharmacogenomics.
1. Early Diagnosis of Pancreatic Cancer
In addition to studying potential salivary transcriptomic and bacterial biomarkers for early detection in pancreatic cancer, he was the UCLA-PI for CAPS3 and the Yale_PI for CAPS5, large prospective multicenter pancreatic cancer screening studies in at-risk individuals, and a member of the International Pancreatic Cancer Screening Consortium.
2. Pancreatic Cystic Neoplasms
Dr Farrell’s clinical and translational research work in the field of pancreatic cystic neoplasms has ranged from studies validating current clinical guidelines, to the development of clinically useful nomograms for patients with pancreatic cysts, to studies aimed at identifying novel pancreatic cyst fluid proteomic and microRNA biomarkers. To this end, he initiated and maintain a pancreatic cyst fluid biobank (2001 to present) which has now over 400 patient pancreatic cyst fluid specimens with clinical and pathologic correlation.
3. Pancreatic Cancer Therapeutics and Personalized Medicine
Most recently, Dr Farrell’s work in the field of pancreatic cancer therapeutics has included exploration of Endoscopic ultrasound guided tumor injection with gene therapy as well as the development and validation of treatment predictive pharmacogenomic markers in pancreatic cancer. In addition to his work looking at SNPs as predictive markers of treatment response and toxicity, in collaboration with the RTOG Co-operative trials group, he validated hENT1 (human equilibrative nucleoside transporter 1) as a predictive marker of gemcitabine responsivity in pancreatic cancer. This has directly led to the development of a commercially available hENT1 based tissue assay and the first hENT1 biomarker driven multicenter treatment trial in pancreatic cancer.
|Pancreas, Prevention||The Cancer of the Pancreas Screening-5 (CAPS5) Study|